Sitagliptin
- CAS No.
- 486460-32-6
- Chemical Name:
- Sitagliptin
- Synonyms
- Sitagliptin base;(3R)-3-Amino-1-[3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,2,4-triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one;Sitagliptin free base;(R)-3-amino-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)butan-1-one;Janumet;Sitagliptin-D4;Sitagliptin API;Unii-qfp0p1dv7z;(3R)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one;(S)-3-amino-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)butan-1-one
- CBNumber:
- CB01449778
- Molecular Formula:
- C16H15F6N5O
- Molecular Weight:
- 407.31
- MDL Number:
- MFCD09838015
- MOL File:
- 486460-32-6.mol
- MSDS File:
- SDS
- TDS File:
- TDS
| Melting point | 114.1-115.7 °C |
|---|---|
| Boiling point | 529.9±60.0 °C(Predicted) |
| Density | 1.61±0.1 g/cm3(Predicted) |
| storage temp. | Store at -20°C |
| solubility | DMSO : ≥ 50 mg/mL (122.76 mM) |
| pka | 7.20±0.10(Predicted) |
| form | Solid |
| color | White to off-white |
| optical activity | -25.4620° (C=0.4167 g/100ml, CHCL3, 20°C, 589nm) |
| InChI | InChI=1S/C16H15F6N5O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22/h4,6,9H,1-3,5,7,23H2/t9-/m1/s1 |
| InChIKey | MFFMDFFZMYYVKS-SECBINFHSA-N |
| SMILES | C(N1CCN2C(C(F)(F)F)=NN=C2C1)(=O)C[C@H](N)CC1=CC(F)=C(F)C=C1F |
| CAS DataBase Reference | 486460-32-6(CAS DataBase Reference) |
| FDA UNII | QFP0P1DV7Z |
| ATC code | A10BH01 |
| EPA Substance Registry System | 1-Butanone, 3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-, (3R)- (486460-32-6) |
| UNSPSC Code | 51111800 |
| NACRES | NA.77 |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|---|---|
| Signal word | Warning |
| Hazard statements | H302-H315-H319-H335 |
| Precautionary statements | P261-P305+P351+P338 |
| target organs | Liver |
| WGK Germany | WGK 3 |
| Storage Class | 11 - Combustible Solids |
| Hazard Classifications | Eye Irrit. 2 STOT RE 2 |
| Hazardous Substances Data | 486460-32-6(Hazardous Substances Data) |
| REACH Registrations | Active |
Sitagliptin price More Price(59)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich | SML3205 | Sitagliptin ≥98% (HPLC) | 486460-32-6 | 10 mg | $98.1 | 2026-04-30 | Buy |
| Sigma-Aldrich | SML3205 | Sitagliptin ≥98% (HPLC) | 486460-32-6 | 50 mg | $395 | 2026-04-30 | Buy |
| TCI Chemical | I1261 | Sitagliptin | 486460-32-6 | 200MG | $79 | 2026-04-30 | Buy |
| TCI Chemical | I1261 | Sitagliptin | 486460-32-6 | 1G | $275 | 2026-04-30 | Buy |
| Usbiological | 289323 | Sitagliptin ≥98% | 486460-32-6 | 5g | $389 | 2026-06-03 | Buy |
Sitagliptin Chemical Properties, Uses, Production
Description
Sitagliptin is an orally-bioavailable selective DPP4 inhibitor that was discovered through the optimization of a class of β-aminoacid-derived DPP4 inhibitors. It lowers DPP4 activity in a sustained manner following once daily administration, preserves the circulating levels of intact GIP and GLP1 following meals in both acute and chronic studies and reduces blood glucose levels without significant increases in hypoglycaemia.
Sitagliptin phosphate (STG) is used to treat DM type 2 because it improves glycemic control by increasing the levels of active incretin hormones, GLP-1 (peptide-1) and GIP (glucose-dependent insulinotropic peptide). The activation of these incretins in β-pancreatic cells causes increased levels of cyclic adenosine monophosphate (cAMP) and intracellular calcium, with subsequent glucose-dependent insulin secretion (2). This hypoglycemic drug belongs to a new class called dipeptidyl peptidase IV inhibitors. STG was approved by the FDA in 2006.
Mechanism of action
Sitagliptin prolongs the activity of proteins that increase the release of insulin after blood sugar rises, such as after a meal. Sitagliptin is a selective inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4), which metabolizes the naturally occurring incretin hormones glucagon-like peptide-1(GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) resulting in enhanced glucose-dependent insulin secretion from the pancreas and decreased hepatic glucose production. Since GLP-1 enhances insulin secretion in the presence of raised blood glucose levels, inhibiting DPP-IV activity will increase and prolong the action of GLP-1 by reducing its rate of inactivation in plasma. Sitagliptin reduces hemoglobin A1c (HbA1c), fasting and postprandial glucose by glucose-dependent stimulation of insulin secretion and inhibition of glucagon secretion. GLP-1 has other widespread effects including delaying gastric emptying, significantly reducing glucagons levels and possible central effects on the appetite.
Pharmacokinetics
Bioavailability of sitagliptin is approximately 87%. Halflife is between 8-14 hours. It is 38% bound to plasma proteins. It undergoes limited metabolism via CYP3A4 and CYP2C8. Elimination is mainly through urine.
Indications
Sitagliptin is approved by the FDA as an adjunct to diet and exercise to improve glycaemic control in patients with T2DM, either as a monotherapy, or in combination with metformin or a peroxisome proliferatoractivated receptor-γ agonist (for example, thiazolidinediones) when the single agent does not provide adequate glycaemic control.
Clinical Use
In October 2006, the U.S. Food and Drug Administration (FDA) approved sitagliptin as monotherapy and as add-on therapy to either of two other types of oral diabetes medications, metformin or thiazolidinediones to improve blood glucose control in patients with type 2 diabetes when diet and exercise are not enough. In March, 2007 it was approved in European Union. Sitagliptin is currently approved in 42 countries. The recommended dose of sitagliptin is 100 mg once daily. It may be taken with or without food. In April, 2007 FDA approved the combination product of sitaglibtin and metformin for type 2 diabetes. In clinical trials of 1-year duration, sitagliptin improved glycaemic control by reducing both fasting and postprandial glucose concentrations, leading to clinically meaningful reductions in glycosylated haemoglobin levels. Monotherapy with sitagliptin 100mg daily decreases mean HbA1c by 0.6- 0.79% (mean difference from placebo). When used in combination with metformin or pioglitazone, the mean reduction is HbA1c is 0.7% and 0.9% respectively. Sitagliptin is considered to be weight neutral and lipid neutral.
Side effects
In clinical trials, sitagliptin demonstrated an overall incidence of side effects comparable to placebo. The most common side effects in studies were upper respiratory tract infection, stuffy or running nose, sore throat, headache and diarrhea. The incidence of hypoglycemia with sitagliptin monotherapy was not significantly different than placebo. Pooled data from 2 monotherapy and 2 combination trials show that the incidence of hypoglycemia was 1.2% and 0.9% for sitagliptin 100mg and placebo respectively.
Drug interactions
Sitagliptin plasma concentrations may be increased modestly (approximately 68%), with cyclosporine which is not expected to be clinically important. Digoxin plasma levels may be increased slightly (approximately 18%), no dosage adjustment is recommended. Although sitagliptin is not as likely to cause hypoglycemia as some other oral diabetes medications, be careful while prescribing any other drug that can potentially lower blood sugar, such as: probenecid, nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin or other salicylates, sulfa drugs, a monoamine oxidase inhibitor (MAOI) or beta-blockers.
Description
Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is a first-in-class oral drug launched for the treatment of type 2 diabetes. It acts by slowing the inactivation of incretins, which are endogenous peptides involved in the physiologic regulation of glucose homeostasis. Incretin hormones, including glucagonlike peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are released by the intestine throughout the day, and levels are increased in response to a meal. When blood glucose concentrations are normal or elevated,GLP-1 and GIP increase the synthesis and release of insulin from pancreatic b cells via intracellular signaling pathways involving cAMP. GLP-1 also lowers glucagon secretion from pancreatic αcells, which leads to reduced hepatic glucose production.
Originator
Merck (US)
Uses
Sitagliptin is a useful pharmaceutical drug. Could be useful for treating intestinal inflammation, diabetes, pre-diabetes, impaired glucose tolerance, hepatitis, and/or inflammatory liver disease.
Uses
Labeled Sitagliptin , intended for use as an internal standard for the quantification of Sitagliptin by GC- or LC-mass spectrometry.
Definition
ChEBI: Sitagliptin is a triazolopyrazine that exhibits hypoglycemic activity. It has a role as a serine proteinase inhibitor, a hypoglycemic agent, an EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor, an environmental contaminant and a xenobiotic. It is a triazolopyrazine and a trifluorobenzene.
brand name
Januvia
Clinical Use
Treatment of type 2 diabetes in combination with metformin or a thiazolidinedione
Synthesis
Sitagliptin can be synthesized via asymmetric hydrogenation of dehydrositagliptin using Rh(I)/tBu JOSIPHOS, or through hydrolysis of a lactam followed by coupling to triazolopiperazine and cleavage of the N-benzyloxy group[1][2][3]. A biocatalytic route produces enantiopure sitagliptin by direct amination of prositagliptin ketone, followed by phosphate salt formation[3]. The product is isolated as its anhydrous phosphoric acid salt by crystallization from aqueous ethanol, or as its phosphate monohydrate from aqueous isopropanol with high purity and yield[1][2]. The First-Generation Process of Sitagliptin[1] is as follow:
Metabolism
Sitagliptin undergoes minimal metabolism, mainly by the
cytochrome P450 isoenzyme CYP3A4, and to a lesser
extent by CYP2C8.
Renal excretion of sitagliptin involves active tubular
secretion; it is a substrate for organic anion transporter-3
and P-glycoprotein.
References
[1]Hansen, K. B., Hsiao, Y., Xu, F., Rivera, N., Clausen, A., Kubryk, M., Krska, S., Rosner, T., Simmons, B., Balsells, J., Ikemoto, N., Sun, Y., Spindler, F., Malan, C., Grabowski, E. J. J., & Armstrong, J. D. (2009). Highly Efficient Asymmetric Synthesis of Sitagliptin. Journal of the American Chemical Society, 131(25), 8798–8804. https://doi.org/10.1021/ja902462q
[2]Hansen, K. B., Balsells, J., Dreher, S., Hsiao, Y., Kubryk, M., Palucki, M., Rivera, N., Steinhuebel, D., Armstrong, J. D., Askin, D., & Grabowski, E. J. J. (2005). First Generation Process for the Preparation of the DPP-IV Inhibitor Sitagliptin. Organic Process Research & Development, 9(5), 634–639. https://doi.org/10.1021/op0500786
[3]Savile, C. K., Janey, J. M., Mundorff, E. C., Moore, J. C., Tam, S., Jarvis, W. R., Colbeck, J. C., Krebber, A., Fleitz, F. J., Brands, J., Devine, P. N., Huisman, G. W., & Hughes, G. J. (2010). Biocatalytic Asymmetric Synthesis of Chiral Amines from Ketones Applied to Sitagliptin Manufacture. Science, 329(5989), 305–309. https://doi.org/10.1126/science.1188934
Sitagliptin Preparation Products And Raw materials
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| AnHui HaiKang Pharmaceutical Co., Ltd. | 86-0556-5800026 17709662922 | wangyu@hkpharm.cn | China | 281 | 55 |
| Hunan Furui Biopharma Technology Co., Ltd. | 15901640172，19275032510 15901640172 | sales03@hn-furui.com | China | 380 | 55 |
| ChemFuture PharmaTech (Jiangsu) Ltd | 5108538618 | suger.wang@chemfuture.com | China | 832 | 65 |
| Chembest Research Laboratories Limited | 021-20908456 | sales@BioChemBest.com | China | 5996 | 61 |
| Beijing HwrkChemical Technology Co., Ltd | 89508211 18501085097 | sales.bj@hwrkchemical.com | China | 9407 | 55 |
| Capot Chemical Co., Ltd | +86 (0) 571 85 58 67 18 | China | 18187 | 66 | |
| Beijing Ouhe Technology Co., Ltd | 13552068683 13522913783 | 2355560935@qq.com | China | 11777 | 60 |
| Shanghai Scientia Pharmaceutical Technology Co., Ltd. | 21-21-54301573 13917723525 | sales@scientiapharm.com | China | 260 | 62 |
| JinYan Chemicals(ShangHai) Co.,Ltd. | 13817811078 | sales@jingyan-chemical.com | China | 9963 | 60 |
| LGM Pharma | 1-(800)-881-8210 | inquiries@lgmpharma.com | United States | 2110 | 70 |
Related articles
- Sitagliptin vs. Linagliptin
- Sitagliptin (CAS 486460-32-6) and Linagliptin (CAS 668270-12-0) are both oral antidiabetic drugs belonging to the DPP-4 inhibi....
- Jul 20,2026
- Sitagliptin: Pharmacological Profile and Therapeutic Efficacy in Type 2 Diabetes
- Sitagliptin, a DPP-4 inhibitor, effectively improves glycaemic control in T2D. Rapid absorption, renal elimination, and proven....
- Jan 2,2024
- Sitagliptin: A Leading DPP-4 Inhibitor for Diabetes Treatment
- Sitagliptin is a popular oral medication used to treat type 2 diabetes. It is classified as a dipeptidyl peptidase-4 (DPP-4) i....
- May 30,2023
View Latest Price from Sitagliptin manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2026-09-17 | Sitagliptin
486460-32-6
|
0.99 | RongNa Biotechnology Co.,Ltd | ||||
 |
2026-09-17 | Sitagliptin
486460-32-6
|
$400.00-1000.00 | 1kg | 99% | 5000 | HEBEI SHENGSUAN CHEMICAL INDUSTRY CO.,LTD | |
 |
2026-09-17 | Sitagliptin.
486460-32-6
|
1g | More Than 99% | 100kg/Month | BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD. |
-
- Sitagliptin
486460-32-6
- 0.99
- RongNa Biotechnology Co.,Ltd
-
- Sitagliptin
486460-32-6
- $400.00-1000.00
- 99%
- HEBEI SHENGSUAN CHEMICAL INDUSTRY CO.,LTD
-
- Sitagliptin.
486460-32-6
- $0.00
- More Than 99%
- BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
